Profile data is unavailable for this security.
About the company
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
- Revenue in USD (TTM)2.50bn
- Net income in USD1.05bn
- Incorporated1996
- Employees1.17k
- LocationUnited Therapeutics Corp1000 SPRING STSILVER SPRING 20910United StatesUSA
- Phone+1 (301) 608-9292
- Fax+1 (301) 608-9291
- Websitehttps://www.unither.com/
More ▼
Mergers & acquisitions
| Acquired company | UTHR:NSQ since announced | Transaction value |
|---|---|---|
| IVIVA Medical Inc | 18.93% | 50.00m |
| Miromatrix Medical Inc | 19.69% | 139.42m |
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Roivant Sciences Ltd | 123.24m | 4.35bn | 9.18bn | 904.00 | 2.25 | 1.51 | 2.15 | 74.48 | 5.07 | 5.23 | 0.1597 | 7.57 | 0.0259 | -- | 3.57 | 136,328.50 | 89.08 | -- | 105.17 | -- | 87.57 | -- | 3,439.02 | -- | 27.77 | -- | 0.0638 | -- | 10.84 | -- | -32.93 | -- | -- | -- |
| Repligen Corp | 607.45m | 14.84m | 9.33bn | 1.78k | 661.79 | 4.73 | 110.43 | 15.36 | 0.2524 | 0.2524 | 10.74 | 35.29 | 0.2255 | 1.43 | 4.87 | 340,689.80 | 0.551 | 4.38 | 0.6179 | 5.03 | 47.73 | 55.43 | 2.44 | 15.91 | 5.24 | -- | 0.2284 | 0.00 | -20.31 | 26.91 | -77.64 | 20.13 | 24.99 | -- |
| Catalent Inc | 4.10bn | -1.30bn | 10.23bn | 17.80k | -- | 2.77 | -- | 2.50 | -7.18 | -7.18 | 22.52 | 20.37 | 0.3878 | 4.09 | 3.00 | 230,224.70 | -12.32 | 2.88 | -14.02 | 3.26 | 17.94 | 31.03 | -31.77 | 6.35 | 1.71 | -0.625 | 0.5758 | 0.00 | -11.22 | 11.59 | -153.00 | -- | 26.69 | -- |
| Exact Sciences Corp | 2.50bn | -204.15m | 11.41bn | 6.50k | -- | 3.58 | 4,640.74 | 4.57 | -1.14 | -1.14 | 13.81 | 17.34 | 0.3937 | 5.32 | 13.82 | 384,579.40 | -3.22 | -9.71 | -3.47 | -10.60 | 73.83 | 74.10 | -8.17 | -28.21 | 2.07 | -- | 0.4311 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
| United Therapeutics Corporation | 2.50bn | 1.05bn | 11.63bn | 1.17k | 12.42 | 2.17 | 10.52 | 4.66 | 21.13 | 21.13 | 50.24 | 120.76 | 0.3891 | 2.50 | 11.31 | 2,138,956.00 | 16.36 | 10.38 | 18.03 | 11.27 | 88.87 | 91.47 | 42.05 | 29.25 | 3.64 | -- | 0.101 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
| Natera Inc | 1.08bn | -434.80m | 11.85bn | 3.28k | -- | 15.15 | -- | 10.95 | -3.80 | -3.80 | 9.41 | 6.40 | 0.7634 | 15.49 | 4.14 | 329,851.00 | -30.66 | -36.17 | -39.20 | -46.60 | 45.52 | 45.88 | -40.16 | -56.15 | 3.96 | -- | 0.3219 | -- | 31.99 | 33.26 | 20.63 | -- | 58.81 | -- |
| Charles River Lbrtrs ntrntl Inc | 4.13bn | 474.62m | 12.03bn | 20.00k | 25.30 | 3.33 | 15.14 | 2.91 | 9.23 | 9.23 | 80.25 | 70.06 | 0.5228 | 8.19 | 5.39 | 206,470.50 | 6.08 | 6.46 | 7.09 | 7.62 | 36.89 | 36.99 | 11.63 | 11.58 | 1.16 | 4.97 | 0.4203 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
| Incyte Corp | 3.77bn | 745.44m | 12.07bn | 2.52k | 16.32 | 2.24 | 14.53 | 3.20 | 3.29 | 3.29 | 16.64 | 24.02 | 0.5827 | 4.52 | 5.50 | 1,492,815.00 | 11.53 | 9.07 | 14.16 | 11.02 | 93.73 | 94.97 | 19.78 | 13.68 | 3.43 | -- | 0.006 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
| BIO-TECHNE Corp | -100.00bn | -100.00bn | 12.15bn | 3.05k | -- | 6.03 | -- | -- | -- | -- | -- | 12.81 | -- | -- | -- | -- | -- | 9.57 | -- | 10.20 | -- | 67.35 | -- | 21.91 | 2.88 | -- | 0.1619 | 24.19 | 2.81 | 12.07 | 4.88 | 25.13 | 12.81 | 0.00 |
| Medpace Holdings Inc | 1.96bn | 312.32m | 12.16bn | 5.80k | 40.00 | 18.07 | 35.79 | 6.20 | 9.81 | 9.81 | 61.73 | 21.72 | 1.23 | -- | 7.31 | 332,680.00 | 19.58 | 13.94 | 46.20 | 23.18 | 27.99 | 28.84 | 15.92 | 15.23 | -- | -- | 0.00 | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
| Sarepta Therapeutics Inc | 1.40bn | 16.90m | 12.63bn | 1.31k | 1,677.67 | 13.14 | 215.07 | 9.00 | 0.0797 | 0.0797 | 14.75 | 10.17 | 0.4466 | 0.5758 | 4.66 | 1,067,960.00 | 0.5378 | -21.63 | 0.6577 | -25.75 | 88.18 | 86.65 | 1.20 | -77.05 | 3.44 | -- | 0.5632 | -- | 33.26 | 32.80 | 23.81 | -- | 6.30 | -- |
| Viatris Inc | 15.43bn | 54.70m | 14.03bn | 38.00k | 278.29 | 0.6911 | 5.02 | 0.9092 | 0.0423 | 0.0423 | 12.81 | 17.05 | 0.3158 | 2.49 | 5.09 | 405,971.10 | 0.112 | 0.0887 | 0.1315 | 0.1061 | 43.64 | 40.29 | 0.3546 | 0.2891 | 1.22 | 2.79 | 0.4696 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
| Neurocrine Biosciences, Inc. | 1.98bn | 369.70m | 14.15bn | 1.45k | 38.67 | 5.93 | 36.09 | 7.14 | 3.64 | 3.64 | 19.47 | 23.72 | 0.6797 | 1.10 | 4.71 | 1,415,714.00 | 12.68 | 9.77 | 15.58 | 12.19 | 98.05 | 98.51 | 18.65 | 14.79 | 2.47 | -- | 0.049 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
Data as of May 03 2024. Currency figures normalised to United Therapeutics Corp's reporting currency: US Dollar USD
50.97%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 4.61m | 9.80% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 4.39m | 9.33% |
| Wellington Management Co. LLPas of 31 Dec 2023 | 3.79m | 8.06% |
| Avoro Capital Advisor LLCas of 31 Dec 2023 | 2.86m | 6.08% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 2.17m | 4.61% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 2.00m | 4.26% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 1.95m | 4.14% |
| Janus Henderson Investors US LLCas of 31 Dec 2023 | 867.89k | 1.84% |
| Geode Capital Management LLCas of 31 Dec 2023 | 779.76k | 1.66% |
| Dimensional Fund Advisors LPas of 31 Dec 2023 | 561.95k | 1.19% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
